Navigation Links
Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
Date:5/6/2008

TORONTO, May 6 /PRNewswire/ - Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use.

Utilizing enzyme-based technology developed at Thermo Fisher Scientific's Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (poly-I) and poly-cytosine (poly-C) in accordance with cGMP (current good manufacturing practice) regulations. Poly-I and Poly-C are polynucleotides that are used as adjuvants, or catalysts, to stimulate an immune response when combined with other substances in a drug. Dalton will supply these polynucleotides to Oncovir, Inc., an innovative pharmaceutical company that will use Poly-I and Poly-C in vaccine development.

"We are delighted to have this opportunity to work with Thermo Fisher Scientific in order to commercialize their novel biopolymers," said Peter Pekos, president and CEO of Dalton Pharma Services. "The agreement is timely due to an increased demand for commercial quantities of these molecules as adjuvants for new vaccines. And, this partnership recognizes Dalton's expertise in cGMP manufacturing and analysis of complex molecules under cGMP conditions."

"By working with partners like Dalton Pharma Services, our innovative technology is finding its way into new and exciting therapeutics," said Mitch Kennedy, global vice president and general manager of Thermo Fisher Scientific's Genomics business. "Ultimately, this allows Thermo Fisher Scientific to advance our mission as a company, which is to enable our customers to make the world healthier, cleaner and safer."

About Dalton Pharma Services

Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton's analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.


'/>"/>
SOURCE Dalton Pharma Services
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
2. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
4. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Benda Pharmaceutical Files Amendment To Form S-1
6. WuXi PharmaTech Schedules First Quarter 2008 Earnings Release on Tuesday, May 27, 2008
7. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
8. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
9. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
10. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
11. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging bio and technology start-ups, is hosting “Celebration Friday” (a ... double event will start with libations and networking at 3:30 p.m. at FITCI’s ...
(Date:4/20/2017)... ... 20, 2017 , ... As part of the Stago ... cases when screening for direct oral anticoagulant. When patients taking direct oral anticoagulants ... parental anticoagulation especially for those at high risk of thrombosis recurrence. ...
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and ... 2 data evaluating galcanezumab for the prevention of migraine ... which will take place April 22-28, 2017, in ... present four abstracts at AAN, including safety and patient ... factors associated with a reduction in monthly migraine headache ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... to the scientific and clinical research community’s growing body of knowledge during its ... in the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, ...
Breaking Biology Technology:
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):